GET DAILY SIGNALSINDP Stock: A Closer Look at Indaptus Therapeutics' Immunotherapy Efforts
Key Takeaways
- INDP is a stock, not an ETF. INDP is the Nasdaq ticker for Indaptus Therapeutics, Inc., a clinical-stage biotechnology company focused on immunotherapy for cancer and viral infections.
- The company is headquartered in New York City and was formerly known as Intec Parent, Inc. before renaming to Indaptus Therapeutics in August 2021.
- Its lead drug candidate, Decoy20, is built on a proprietary "Decoy" platform using inactivated bacteria to stimulate the immune system against tumors and certain viruses.
- As a pre-revenue, clinical-stage developer, the company has no product sales and relies on equity financing to fund research and clinical trials.
- Recent corporate developments include a 1-for-28 reverse stock split in 2025 and a strategic investment transaction that shifted control of the company and prompted a search for a potential business combination.
Introduction
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to treat cancer and certain viral infections. Investors follow INDP because the company represents a speculative, early-stage bet on a novel approach to activating the body's immune system. Unlike established pharmaceutical firms, Indaptus generates no meaningful product revenue and is still working to advance its lead candidate through clinical development. When screening for comparable names in the sector, I sometimes cross-reference with Tickeron’s AI tools to gain additional perspective on industry peers.
Company Background and History
Indaptus Therapeutics is headquartered at 3 Columbus Circle in New York, New York. The company was previously named Intec Parent, Inc. and adopted the Indaptus Therapeutics name in August 2021. Its shares trade on the Nasdaq Capital Market under the symbol INDP. The company operates within the healthcare sector and the biotechnology industry, an area defined by long development timelines, heavy research spending, and substantial regulatory oversight from agencies such as the U.S. Food and Drug Administration (FDA).
Business Model and Technology
Indaptus is built around what it calls the "Decoy" platform, a technology based on single strains of attenuated (weakened) and killed, non-pathogenic Gram-negative bacteria. The core scientific premise is that triggering a broad package of immune-system signals—rather than a single pathway—can produce stronger anti-tumor and anti-viral responses. These bacterial "decoys" are designed to activate multiple immune receptors, including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and the STING (Stimulator of Interferon Genes) pathway, which work together to alert and mobilize the immune system.
The company's lead clinical candidate is Decoy20. Indaptus has studied Decoy20 for the treatment of advanced solid tumors and has reported preclinical activity against chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections. As a clinical-stage company, its primary revenue sources are essentially nonexistent; instead, the business model depends on raising capital through equity financings to fund ongoing research, clinical trials, and general operations.
Market Position and Competitive Landscape
Indaptus occupies a niche position within the crowded immuno-oncology field. Its differentiated angle is the use of inactivated bacteria to deliver a multi-targeted immune stimulus intravenously, an approach the company positions as distinct from single-agent checkpoint inhibitors and other more narrowly targeted immunotherapies. However, the company competes against far larger biotechnology and pharmaceutical firms with deeper resources, broader pipelines, and established commercial infrastructure. Because its candidates remain in clinical and preclinical stages, Indaptus has not yet established a commercial market position or proven the efficacy and safety of its platform in large-scale trials.
Why Investors Follow INDP
Investor interest in INDP centers on its potential as an early-stage platform play. A successful Decoy20 trial or partnership could validate the underlying technology and dramatically reshape the company's financial profile, which currently shows no product revenue and ongoing net losses typical of pre-commercial biotechs. The company's broad applicability—spanning oncology and chronic viral infections—offers a potentially large addressable market if the platform proves effective.
Recent corporate developments have also drawn attention. In June 2025, Indaptus completed a 1-for-28 reverse stock split to support its Nasdaq listing. In December 2025, the company entered into a securities purchase agreement with investor David E. Lazar, who acquired preferred stock and became the beneficial owner of roughly 96% of the company's common stock on an as-converted, fully diluted basis. As part of that transaction, Indaptus announced plans to pursue a strategic transaction involving an investment in or acquisition of an operating business—an initiative that has shifted the company's direction beyond its original drug-development focus.
Risks and Important Considerations
Indaptus carries the elevated risks typical of clinical-stage biotechnology companies. The company has a limited operating history, is not profitable, and has disclosed in its SEC filings that conditions exist that raise substantial doubt about its ability to continue as a going concern. It will likely need to raise additional capital, which can dilute existing shareholders.
Beyond funding risk, the company faces the inherent uncertainty of clinical trials, which are lengthy, expensive, and may fail to demonstrate safety or efficacy. Regulatory approval is not guaranteed, and even successful science may not translate into commercial success. The recent change in control and the planned pursuit of a strategic business combination add further uncertainty, including potential management changes, significant shareholder dilution, and reduced voting power for existing stockholders. Investors should also note that micro-cap biotech stocks can be highly volatile and illiquid.
Using AI Tools in Biotech Research
In my own analysis of names like INDP, I have found Tickeron’s AI Screener helpful for quickly comparing technical indicators, fundamentals, and industry trends across early-stage companies. It allows users to apply customizable filters and AI-generated signals to narrow down opportunities that match specific strategies, which can be useful when evaluating speculative biotech positions alongside more established names.
Conclusion
Indaptus Therapeutics is a small, clinical-stage biotechnology company pursuing an unconventional immunotherapy platform aimed at both cancer and chronic viral infections. Its pre-revenue business model, reliance on external capital, and ongoing strategic repositioning make it a high-risk, high-uncertainty investment proposition. For investors interested in early-stage biotech, INDP offers a window into the speculative end of the healthcare sector—one where scientific promise and meaningful financial risk coexist.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INDP saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for INDP moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 41 similar instances where the indicator exited the overbought zone. In 37 of the 41 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INDP as a result. In 87 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for INDP turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 44 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The 50-day moving average for INDP moved above the 200-day moving average on October 22, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where INDP advanced for three days, in 167 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
INDP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 66 of 90 cases where INDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. INDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (38.898) is normal, around the industry mean (3.498). P/E Ratio (-0.933) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INDP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology